Also known as PTH(1-34) · Forteo · Bonsity · recombinant parathyroid hormone
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
Teriparatide is the first 34 amino acids of parathyroid hormone (PTH), the body’s master regulator of calcium. It is one of the few osteoporosis drugs that is genuinely anabolic — it builds new bone rather than just slowing its loss — and it does so by exploiting a striking biological paradox. The same PTH signal that dissolves bone when it is chronically elevated stimulates bone formation when it is delivered as a brief, once-daily pulse. Teriparatide turns that timing trick into a therapy.
Parathyroid hormone is the body’s calcium thermostat, and the N-terminal 1-34 fragment retains its full receptor activity — which is why teriparatide is that fragment rather than the whole 84-residue hormone. Its defining feature is the dose-pattern paradox: a continuously high PTH level (the disease state of hyperparathyroidism) leaches calcium from bone, but a short daily spike tips the balance toward the bone-building osteoblasts. Teriparatide (Forteo, approved 2002) was among the first treatments to add bone rather than merely preserve it, used in severe osteoporosis and high fracture risk.
It also carries one of the more instructive drug-safety stories. Teriparatide launched with a black-box warning for osteosarcoma, a bone cancer seen when rats were given very high, lifelong doses — which translated into a strict two-year lifetime limit on use in people. Over nearly two decades of post-marketing data that signal did not materialize in humans, and in 2020 the FDA removed the boxed warning and the lifetime restriction. It is a useful case of a precautionary animal-derived warning being revised as real-world human evidence accumulated.
For a reference catalog, teriparatide is a clean example of how *timing*, not just the molecule, determines a hormone’s effect — and of how a peptide fragment can outperform the full hormone for a specific therapeutic goal.
Agonist at the PTH1 receptor on osteoblasts. Intermittent (once-daily) exposure favors osteoblast activity and new bone formation; continuous elevation (as in hyperparathyroidism) instead drives osteoclastic resorption. The therapeutic effect depends entirely on the pulsatile dosing.
Behind every vial of Teriparatide (PTH 1-34) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Teriparatide (PTH 1-34), specifically, is brought into being.
On paper, Teriparatide (PTH 1-34) is C181H291N55O51S2 — about 4,117.8 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Teriparatide (PTH 1-34) means roughly 34 coupling cycles on the synthesizer — one protected residue added at a time, which is also 34 chances for an incomplete coupling to seed a deletion impurity. At this length the growing chain is prone to aggregation on the resin, making every later cycle harder — long sequences are where small per-cycle losses compound into a messy crude.
The crude mixture — Teriparatide (PTH 1-34) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of Teriparatide (PTH 1-34) proves itself: identity confirmed by mass spectrometry against its ~4,117.8 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Teriparatide (PTH 1-34) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Teriparatide is recombinant human PTH(1-34), expressed in E. coli and purified to a defined 34-residue peptide. Because it is the minimal active fragment rather than the full 84-residue hormone, it can be manufactured and characterized more like a long synthetic/recombinant peptide than a large folded protein — identity by mass spectrometry and peptide mapping, with potency confirmed functionally.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Teriparatide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Teriparatide is PTH(1-34), the active fragment of parathyroid hormone, used as a recombinant injectable (Forteo) for osteoporosis. Unlike most bone drugs, it is anabolic — it builds new bone.
It is about timing. A brief once-daily pulse of PTH favors bone-building osteoblasts, while a continuously high level (as in hyperparathyroidism) drives bone resorption. Teriparatide uses the pulsatile pattern deliberately.
The original 2-year lifetime limit and osteosarcoma boxed warning — based on high-dose rat studies — were removed by the FDA in 2020 after long-term human data did not show that risk.
No — this is a research and educational reference, not dosing guidance.